Newsfeeds - Spark Newswire

1 minute read

Zealand Pharma Announces Outcome Of Phase 1B Clinical Trial With Dapiglutide; Dapiglutide Was Assessed To Be Safe And Well Tolerated Following 4 Weeks Of Dosing In Humans

Today, 12:44 PM

Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces topline results from its Phase 1b

ZEAL

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 12:44 PM

Gainers

ADMA

10 minute read

Earnings Scheduled For November 11, 2021

By Benzinga Insights

Today, 12:44 PM

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.

ACHR

2 minute read

Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement To ‘Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism’; Financial Details Not Disclosed

By Bill Haddad

Today, 12:44 PM

Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for

ZEAL

2 minute read

Zealand Pharma Announces Presentation Of Preclinical Data On Amylin Analogue And Clinical Data On Glucagon-GLP1 Dual-Agonist At The Obesity Society Annual Meeting

By Benzinga Newsdesk

Today, 12:44 PM

Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced it will present preclinical

ZEAL

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 12:44 PM

ALT

2 minute read

News

Zealand Pharma Presents Data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models – in Contrast to Short-acting GLP-2

By Benzinga Newsdesk

Today, 12:44 PM

ZEAL

7 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 12:44 PM

Friday morning, 94 companies reached new 52-week lows.

AAOI

6 minute read

The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO

By Shanthi Rexaline

Today, 12:44 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)

ABVC

7 minute read

FDA
News

Zealand Pharma Highlights Launch Of ZEGALOGUE Injection, Advances Pipeline Across Multiple Therapeutic Areas

By Benzinga Newsdesk

Today, 12:44 PM

Product Launch Update Dasiglucagon is a stable glucagon analog commercially available as Zegalogue® (dasiglucagon) injection, and indicated for the treatment of severe hypoglycemia in people with diabetes aged 6 and

ZEAL